L-deprenyl induces aromatic L-Amino Acid Decarboxylase (AADC) mRNA in the rat substantia nigra and ventral tegmentum: An in situ hybridization study

Molecular and Chemical Neuropathology

Volumn 35, Issue 1-3, 1998, Pages 149-155

  Li, Xin Min ^a   Juorio, Augusto V ^a   Qi, Jin ^a   Boulton, Alan A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

DOPA decarboxylase; Dopamine; L Deprenyl; Parkinson disease; Substantia nigra; Ventral tegmentum

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; SELEGILINE;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; DOPAMINE METABOLISM; DRUG EFFECT; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

ANIMALIA; PARKINSONIA;

EID: 0032964181     PISSN: 10447393     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02815121     Document Type: Article

References (26)

1. Birkmayer W., Riederer P., Ambrozi and Youdim M. B. (1977) Implications of combined treatment with "Madopar" and L-deprenyl in Parkinson's disease, a long term study. Lancet 1, 439-443.
2. Carrillo M., Kanai M., Nokubo M., and Kitani K. (1991) (-)-Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci. 48, 517-521.
3. Cho S., Duchemin A.-M., Neff N. H., and Hadjiconstantinou M. (1996) Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monoamine oxidase-A. Eur. J. Pharmacol. 314, 51-59.
4. Eaton M. J., Gudehithlu K. P., Silvia C. P., Quach T., Hadjiconstantinou M., and Neff N. H. (1993) Distribution of aromatic L-amino acid decarboxylase mRNA in mouse brain by in situ hybridization histology. J. Comp. Neurol. 337, 640-654.
5. Gibson C. J. (1987) Inhibition of MAO B, but not MAO A, blocks DSP-4 toxicity on central NE neurons. Eur. J. Pharmacol. 141, 135-138.
6. Glover V., Sandler M., and Owen F. (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265, 80-81.
7. Hornykiewicz O. (1966) Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18, 925-964.
8. Jaeger C. B., Rugiero D. A., Albert V. R., Park D. H., Joh T. H., and Reis D. J. (1984) Aromatic L-amino acid decarboxylase in the rat brain: immunocytochemical localization in neurons of the brain stem. Neuroscience 11, 691-713.
9. Karoum F., Chuang L. W., Eisler T., Calne D. B., Liebowitz M. R., Quintin F. M., et al. (1982) Metabolism of (-)-deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: A biochemical assessment. Neurology 32, 503-509.
10. Knoll J. (1988) Extension of life span of rats by long-term (-) deprenyl treatment. Mt. Sinai J. Med. 55, 67-74.
11. Kosofsky B. E., Geneva L. M., and Hyman S. E. (1994) Postnatal age defines specificity of immediate early gene induction by cocaine in developing rat brain. J. Comp. Neurol. 351, 27-40.
12. Li X.-M., Juorio A. V., Paterson I. A., Zhu M.-Y., and Boulton A. A. (1992) Specific irreversible MAO B inhibitors stimulate gene expression of aromatic L-amino acid decarboxylase in PC12 cells. J. Neurochem. 59, 2324-2327.
13. Li X.-M., Juorio A. V., and Boulton A. A. (1993a) NSD-1015 alters the gene expression aromatic L-amino acid decarboxylase in PC12 pheochromocytoma cells. Neurochem. Res. 18, 915-919.
14. Li X.-M., Juorio A. V., Paterson I. A., Walz W., Zhu M.-Y., and Boulton A. A. (1993b) Gene expression of aromatic L-amino acid decarboxylase in cultured rat glial cells. J. Neurochem. 59, 1172-1175.
15. Li X.-M., Juorio A. V., and Boulton A. A. (1995) Some new mechanisms underlying the actions of (-)-deprenyl: possible relevance to neurodegeneration. Prog. Brain Res. 106, 99-112.
16. Lloyd K. G. and Hornykiewicz O. (1970) Parkinson's disease, activity of L-dopa decarboxylase in discrete brain regions. Science 170, 1212, 1213.
17. Marsden C. D. (1990) Parkinson's disease. Lancet 335, 948-952.
18. Paterson I. A., Juorio A. V., and Boulton A. A. (1990) 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J. Neurochem. 55, 1827-1837.
19. Paxinos G. and Watson C. (1982) Rat Brain in Stereotaxic Coordinates. Academic, New York.
20. Robins E., Robins J. M., Croninger A. B., Moses S. G., Spencer J., and Hudgens R. W. (1967) The low level of 5-HTP decarboxylase in human brain. Biochem. Med. 1, 240-251.
21. Salo P. T. and Tatton W. G. (1992) Deprenyl reduces the death of motoneurons caused by axotomy. J. Neurosci. Res. 31, 394-400.
22. Tatton W. G. and Chalmers-Redman R. M. E. (1997) Apoptosis in neurogenerative disorders: potential therapy by modifying gene transcription. J. Neurol Transm. 49, Suppl, 245-268.
23. The Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328, 176-183.
24. Youdim B. M. H., Heldman E., Pollard H. B., Fleming P., and McHugh E. (1986) Contrasting monoamine oxidase activity and tyramine induced catecholamine release in PC 12 and chromaffin cells. Neuroscience 19, 1311-1318.
25. Yu P. H., Davis B. A., Durden D. A., Terleckyj I., Nicklas W. G., and Boulton A. A. (1994) Neurochemical and neuroprotective effects of some aliphatic propargylamines: new selective non-amphetamine-like MAO-B inhibitors. J. Neurochem. 62, 697-704.
26. Zsilla G., Földi P., Held G., Székely A. M., and Knoll J. (1986) The effect of repeated doses of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Pol. J. Pharmacol. Pharm. 38, 57-67.